Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Brexit
The second round of the UK’s talks on exiting the EU by the end of the year have been called off over COVID-19, but whether this is a temporary derailment or a more structural issue for the UK’s planned EU separation is the question emerging.
As the UK looks to its future healthtech regulatory model after Brexit, the ABHI’s regulatory director Phil Brown suggests a system whereby the same product data can be used as the basis for entry not only to the EU, but also to global markets.
With the obvious distractions of coronavirus, the UK Medicines and Medical Devices bill has entered its second reading in parliament, accompanied by a drive for it to succeed from the government and opposition parties.
Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.
Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”
ABHI director of value and access Luella Trickett talks about the importance of real-world evidence in product development and value-based procurement in secondary care in the UK.
UK health minister Baroness Blackwood will introduce the new UK Medicines and Medical Devices Bill before Parliament today, just before the House of Commons goes into recess. The government wants new legislation for devices and medicines in place before the end of the Brexit transition period.
In this week's podcast, Medtech Insight executive editor Ashley Yeo chats with deputy editor Reed Miller about the UK's departure from the EU on 31 January, and what that means for the region's medtech industry.
Brexit could hardly have come at a worse time for the medtech sector in Europe. The implementation of the new medtech regulations is behind schedule, and threatening the survival of many medtech products. Now the UK is looking at its own regulatory route. Will this mean regulatory divergence?
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.